TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$336 Million

Apogee Therapeutics, Inc.

Initial Public Offering

Active Bookrunner, July 2023

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. (“Apogee” or “the Company”) is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. The Company’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Apogee’s two most advanced programs are APG777 and APG808, which Apogee is initially developing for the treatment of AD and COPD, respectively.